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Abstract: Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which 
requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of 
inﬂ  ammatory cytokines and effective in the treatment of AD. Various clinical trials have 
shown its long-term safety and efﬁ  cacy in pediatric and adult patients suffering from mild 
to moderate AD. In this article we discuss data which has assessed the impact of AD on the 
patient’s quality of life, and the consequent role of topical anti-inﬂ  ammatory therapy for long-
term AD treatment.
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Introduction
Atopic dermatitis (AD) is a chronic relapsing cutaneous disease characterized by dry 
and scaly skin, inﬂ  ammation, and intense itching. A point prevalence up to 30% in some 
industrialized countries and a steady increase in disease prevalence has been observed 
(Zuberbier et al 2006). AD is more frequent in children; up to 20% of children are 
affected (Breuer et al 2005). In adults, we have previously shown a point prevalence 
of 1.6% if current symptoms are considered (Worm et al 2006). In addition to genetic 
factors, several trigger factors play a role in the development of AD (Leung and Bieber 
2003). These include allergens, microbial infections and, as recently shown, a disrupted 
skin barrier function (Marenholz et al 2006).
Accordingly, the treatment of AD is complex. One major basic measure is the 
regular usage of emollients. Furthermore, an anti-inﬂ  ammatory topical treatment is 
crucial to ending the itching-scratching cycle in affected patients. Corticosteroids have 
long been the standard treatment; calcineurin inhibitors now represent an additional 
treatment option. These offer long-term treatment, with stabilization of the chronic 
disease and an improvement in quality of life. This is of great importance, as it is 
known that AD has a greater impact on the quality of life than the other chronic skin 
diseases (Finlay and Khan 1994). In addition, AD has a negative effect on the mental 
health of patients (Kiebert et al 2002).
The recently published International Study Of Life with ATopic Eczema (ISOLATE) 
enrolled a total of 2002 patients from eight countries (France, Germany, Mexico, 
Netherlands, Poland, Spain, UK, and US). It presents for the ﬁ  rst time a large amount 
of quality of life data from affected AD patients. In the following we will review 
published clinical data on pimecrolimus and discuss its impact on the medical treatment 
of AD patients.
Structure and mechanism
Pimecrolimus is an ascomycin macrolactam derivative and was developed 
speciﬁ  cally for the treatment of inﬂ  ammatory skin diseases. By binding to the 
cytosolic receptor macrophilin-12 with high afﬁ  nity in T lymphocytes and forming Therapeutics and Clinical Risk Management 2007:3(6) 1022
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a complex structure, the activity of the calcium dependent 
phosphatase calcineurin is blocked (Figure 1). The 
inhibition of calcineurin prevents from NF-AT dependent 
transcription of genes encoding the TH2-type cytokines 
IL-4 and IL-10 but also TH1-type cytokines IL-2 and 
IFN-γ. Pimecrolimus also decreases cytokine production 
from mast cells and inﬂ  uences the release of preformed 
mediators (Zuberbier et al 2001; Stuetz et al 2006), while 
not affecting Langerhans cells (Meingassner et al 2003; 
Hoetzenecker et al 2004).
Infants as well as children with extended atopic lesions 
are at high risk for local side effects and systemic absorption 
through the skin. Therefore, even minimal systemic absorption 
is an important safety aspect in infants. It is essential to 
exclude a possible systemic exposure to pimecrolimus when 
applied extensively on affected skin. However, previous 
pharmacokinetic studies in pedriatic patients have shown 
that systemic absorption of pimecrolimus is low, even in 
infants with large body surface area involvement (Harper 
et al 2001; Billich et al 2004; Draelos et al 2005; Meingassner 
et al 2005). This low level of systemic absorption might 
be explained by the lipophilicity of the molecule and its 
high molecular weight (810 Da). Consequently, none of 
the systemic side effects associated with corticosteroids are 
expected with pimecrolimus.
Low systemic drug exposure in pimecrolimus treated 
infants was observed in an open-label, non-controlled study 
by Staab et al (2005). The drug concentrations remained 
below 2 ng/mL in most cases (96%).
Clinical efﬁ  cacy and safety
The efﬁ  cacy and safety of pimecrolimus was analysed in vari-
ous clinical studies related to short- and long-term manage-
ment of AD and early intervention. Especially infants from 3 
to 12 months and children up to 17 years of age were treated 
with pimecrolimus in the context of a novel nonsteroidal 
therapy. A signiﬁ  cant reduction in AD ﬂ  ares and pruritus, 
and a reduced application rate of topical corticosteroids 
were observed. In addition, systemic adverse events were 
rare, probably unrelated to pimecrolimus and not clinically 
relevant. In the majority of cases only local reactions occurred 
such as skin burning, ﬂ  ush symptomatic, and skin irritation, 
which normally disappeared within 1 week of treatment. 
On the other hand, a slightly increased incidence of viral 
Figure 1 Mechanism of calcineurin inhibitors: By binding to macrophillin-12, calcineurin is blocked which in turn inhibits the translocation of NF-AT into the nucleus and the 
transcription of pro-inﬂ  ammatory cytokines of activated T cells. Adapted with permission from Eichenﬁ  eld LE, Beck L. 2003. Elidel (pimecrolimus) cream 1%:   A nonsteroidal 
topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol, 111:1153–68. Copyright© 2003 Elsevier.
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skin infections during the application of pimecrolimus has 
been shown; in this case, it is recommended to interrupt the 
application until the infection subsides (Eichenﬁ  eld et al 
2002; Kapp et al 2002; Wahn et al 2002; Ho et al 2003; 
Papp et al 2005).
In adult patients, the treatment with pimecrolimus resulted 
also in a signiﬁ  cant reduction of topical corticosteroids usage. 
Furthermore, a pronounced reduction of pruritus and number 
of AD ﬂ  ares throughout the treatment period were observed. 
During therapy, quality of life also improved by 35% in 
patients using pimecrolimus, compared with 11% in the 
control group after 6 months (Meurer et al 2004).
Currently, pimecrolimus has been approved as second-
line therapy for the treatment of mild to moderate AD in 
non-immunocompromized children  2 years old and in 
adult patients. In 2005 the US Food and Drug Administration 
(FDA) modified the labeling of pimecrolimus (and 
tacrolimus) and included a black box warning which is the 
highest level of ﬁ  ve possible warning categories found in 
the package insert (Aaronson 2006). This warning states that 
although a direct causal relationship has not been established, 
cases of malignancy (eg, skin and systemic) have been 
reported in patients treated with pimecrolimus, implying 
that this treatment bears a potential risk to patients if used 
in a long-term manner.
In contrast, data from randomized controlled studies 
suggest that pimecrolimus poses a lower risk of cancer than 
its vehicles or topical corticosteroids (Hultsch et al 2005). 
In the case of pimecrolimus, out of 19,000 treated subjects 
2 cases of cancers were reported (Hultsch 2005), while 
out of 4000 subjects treated with corticosteroids or the 
comparator vehicle, 5 cases of cancers were described.
Impact of pimecrolimus 
on the quality of life
For many patients and caregivers of children with AD, the 
skin disease was not restricted only to the visible symptoms, 
but also had a severe impact on their overall quality of life. 
The data from ISOLATE demonstrate that 75% of patients 
and caregivers regarded an improvement in their quality of 
life via effective AD control as most important (Zuberbier 
et al 2006).
The characteristics of the study population are sum-
marized in Figure 2. About 50% of AD patients had been 
diagnosed in the ﬁ  rst 3 years of life, 24% after the age of 
18 years. Over 50% suffered from moderate AD and 32% 
had a severe skin status. On average, every patient suffered 
from 9 ﬂ  ares per year with an average duration of 15 days, 
resulting in 136 ﬂ  are days per year. During a ﬂ  are, sleep 
disturbance occurred in an average of 7 nights and patients 
woke up almost twice a night.
Regarding the consequences of AD ﬂ  ares on patient’s 
lifestyle, 86% of AD patients avoided at least one type of 
everyday activity during a ﬂ  are period, eg, swimming or 
wearing revealing clothes. In the same way parameters like 
school/work life, home life, and social life were altered dur-
ing a ﬂ  are in almost 33% of the patients. In 9% of patients, 
school/work performance and productivity was inﬂ  uenced 
Figure 2 Disease characteristics in patients (children, adolescents, adults) with AD (n = 2002).   Adapted with permission from Zuberbier T, Orlow SJ, Paller AS, et al. 2006. 
Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol, 118:226–32. Copyright© 2006 Elsevier.
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negatively. Patients with AD were absent about 2.5 days per 
year due to AD from school/work (Figure 3).
The ISOLATE data also demonstrate the emotional 
aspects of AD. At least 43% of the patients suffering 
from AD were fairly or very concerned about being seen 
in public while experiencing a ﬂ  are. More than 1 in 3 
patients (36%) was impaired by a ﬂ  are in terms of self-
conﬁ  dence. Every second patient (51%) was always or 
sometimes unhappy or depressed respectively, while 27% 
of the patients had experienced bullying because of their 
AD (Table 1).
Further aspects of patients’ social lives were affected by 
AD ﬂ  ares, including relationships. About 30% of the patients 
or caregivers believed that either their or their child’s AD had 
an effect on other household members. Twenty-one percent 
of adult patients indicated problems in forming relation-
ships with a partner, and 12% had experienced difﬁ  culties 
in established relationships due to an AD ﬂ  are. Furthermore, 
almost half of the patients (42%) felt embarrassed to be seen 
by their partner during a ﬂ  are (Table 2).
The ISOLATE data also demonstrated data on the 
“quality of life index for atopic dermatitis” (QoLIAD) for AD 
patients older than 13 years and the “parent’s index of quality 
of life – atopic dermatitis” (PIQoL-AD) for caregivers of 
children aged 2–13 years. While adolescent and adult patients 
were worried (73%) and embarrassed (44%) about their 
appearance and did not want people to see their skin during 
a ﬂ  are (63%), the caregivers were concerned regarding the 
choice of clothes (71%) and had side effects of AD treatments 
in mind (64%) (Table 3). The topical corticosteroid treatment 
especially worried about 89% of the caregivers and 83% of 
adolescent and adult patients.
The perceptions of patients and caregivers regarding 
topical AD treatment are shown in Table 4. Skin atrophy 
after the application of topical corticosteroids still remains 
the most important anticipated side effect.
Figure 3  Lifestyle consequences of AD ﬂ  ares on patients and caregivers (n = 2002).   Adapted with permission from Zuberbier T, Orlow SJ, Paller AS, et al. 2006. Patient 
perspectives on the management of atopic dermatitis. J Allergy Clin Immunol, 118:226–32. Copyright© 2006 Elsevier.
Table 1 Emotional aspects of AD (n = 2002)
Emotional aspects  Total [%]
•  Fairly or very concerned about being seen in public  43
•  With effect on self-conﬁ  dence  36
•  Unhappy or depressed  51
•   Has been teased or bullied because of AD at some
time during life  27
Adapted with permission from Zuberbier T, Orlow SJ, Paller AS, et al. 2006. Patient 
perspectives on the management of atopic dermatitis. J Allergy Clin Immunol, 118:226–32. 
Copyright© 2006 Elsevier.
Table 2 Effects of AD on relationships (n = 2002) 
Effects of AD on relationships  Total [%]
•  AD has an effect on other household members  30
• Difﬁ  culty to form relationships with a partner  36
•  Relationship problems with an existing partner  51
•   Feeling awkward about a partner touching or seeing 
the body during a ﬂ  are  27
Adapted with permission from Zuberbier T, Orlow SJ, Paller AS, et al. 2006. Patient 
perspectives on the management of atopic dermatitis. J Allergy Clin Immunol, 118:226–32. 
Copyright© 2006 Elsevier.
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The treatment with pimecrolimus was associated with a 
statistically signiﬁ  cant improvement in quality of life after 6 
months of treatment compared to baseline in adult patients and 
caregivers. Interestingly, those caregivers who had previously 
reported concerns about local treatment with corticosteroids 
reported a signiﬁ  cantly greater improvement in quality of life 
than did those without such concerns. The application of cor-
ticosteroids on the other hand was less frequent and for shorter 
periods than recommended by the doctor. This is in line with 
previous studies showing the steroid sparing effect during 
long-term pimecrolimus treatment (Meurer et al 2004).
Other recent studies have also reported the positive impact 
of pimecrolimus therapy on patients’ quality of life (McKenna 
et al 2006; Sunderkötter et al 2006). The data were assessed 
with the “Dermatology Life Quality Index” (DLQI) and the 
“Children’s Dermatology Life Quality Index” (CDLQI) 
respectively and the PIQoL-AD. In the course of treatment 
a signiﬁ  cant improvement in the quality of life could be 
demonstrated (DLQI p   0.0001, PIQoL-AD p   0.052) 
together with an effective and well tolerated therapy.
Conclusion
AD is one of the most frequent chronic inﬂ  ammatory skin 
diseases, and it has a great impact on the quality of life 
on affected patients. Data from the ISOLATE study have 
allowed for the ﬁ  rst time a detailed analysis of social and 
emotional consequences in AD patients. The severity of 
these consequences indicates the necessity of effective 
treatment of AD. These consequences can be alleviated 
via long-term topical treatment with topical calcineurin 
inhibitors.
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